ArticleJournal of pharmacy & bioallied sciences2025
Evaluation of Salivary Biomarkers in the Early Detection of Oral Squamous Cell Carcinoma.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of salivary biomarkers predicting oral disease activity in apparently healthy individuals.Bioinformation · 2026Article
- Key Early Changes in Oral Squamous Cell Carcinogenesis Are Accelerated by Ectopic BMI1 Expression.Cancer research communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The most prevalent malignant tumor affecting the oral cavity is called oral squamous cell carcinoma (OSCC). Improving patient outcomes and survival rates requires early identification. Salivary biomarkers have drawn a lot of interest as noninvasive diagnostic methods for early OSCC detection. Materials and Methods: One hundred people participated in a cross-sectional research, 50 of whom had been diagnosed with OSCC and 50 of whom were healthy controls. Samples of unstimulated saliva were taken from each participant. The enzyme-linked immunosorbent test (ELISA) was used to measure the salivary levels of three biomarkers: tissue polypeptide-specific antigen (TPSA), matrix metalloproteinase-9 (MMP-9), and interleukin-6 (IL-6). Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic accuracy of the biomarker levels and compare them across groups using statistical analysis. Results: OSCC patients had substantially higher salivary levels of TPSA (12.5 ± 2.4 ng/mL), MMP-9 (400 ± 30 ng/mL), and IL-6 (35.2 ± 7.1 pg/mL) than healthy controls (TPSA: 4.2 ± 1.1 ng/mL; Conclusion: Salivary biomarkers with intriguing potential for OSCC early detection include TPSA, MMP-9, and IL-6. They are useful instruments for screening high-risk people because of their noninvasiveness and excellent diagnostic precision. It is advised that further longitudinal research be done to confirm these results and investigate how they may be used in therapeutic settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.